Medicinal Herbs

Agrimony is a tannin-rich European herb from the Rosaceae family, used traditionally for mild diarrhea and inflammation of the oral and pharyngeal mucosa. Commission E approved it for mild nonspecific acute diarrhea and mild inflammation of the mucous membranes of the mouth and throat. The EMA granted traditional use status for mild diarrhea, symptomatic treatment of minor oral mucosal inflammation, and minor skin inflammation. No ESCOP monograph exists. The astringent action is attributed to catechin-type tannins (3-10%), particularly agrimoniin. Clinical evidence is essentially absent; approvals rely on pharmacological rationale and traditional use. The safety profile is favorable with no known drug interactions.

Aloe vera is paradoxically the most globally popular wound-healing plant yet has the weakest formal European regulatory endorsement among the herbs in this knowledge base. Commission E approved it only for constipation (oral latex); there is no European monograph for topical wound healing. The EMA/HMPC monograph addresses the dried latex laxative use, not the gel for skin. Despite this regulatory gap, clinical evidence -- particularly meta-analyses for burn wound healing -- shows statistically significant benefits (4-9 days faster healing). The evidence is hampered by small, heterogeneous, and often low-quality trials. Aloe vera gel contains acemannan (a glucomannan polysaccharide) as its primary wound-healing compound, which stimulates macrophages, promotes angiogenesis, and increases collagen synthesis.

American Skullcap is a North American herb with a long tradition of use by Western herbalists as a calming nervine for anxiety, nervous tension, and sleep difficulties. It should not be confused with Baikal Skullcap (Scutellaria baicalensis), which is a TCM herb with a different phytochemical profile and substantially more research. American Skullcap contains flavonoids including baicalin, scutellarein, and scutellarin, though in different proportions than its Baikal relative. Two small RCTs provide preliminary evidence: Wolfson & Hoffmann (2003) showed reduced anxiety in 19 healthy volunteers, and Brock et al. (2014) demonstrated improved global mood in 43 participants. No Commission E, ESCOP, or EMA monograph exists. Historical reports of skullcap hepatotoxicity have been traced to adulteration with germander (Teucrium spp.), and properly authenticated S. lateriflora appears to have a good safety profile. The herb remains a staple in British and North American herbal practice despite the paucity of clinical trial data.

Andrographis paniculata has robust clinical evidence for reducing URTI symptoms, with multiple RCTs and a systematic review/meta-analysis showing significant superiority over placebo. The Kan Jang product (Andrographis + Eleutherococcus senticosus) is the most-studied formulation, with Swedish and Armenian trials demonstrating reduced symptom duration and severity. However, the EMA/HMPC declined to establish a monograph because the requirements for either "well-established use" or "traditional use" within the EU framework were not met. This is primarily because Andrographis is not part of European traditional medicine (originating from Ayurvedic and Traditional Chinese Medicine). It is registered as an approved herbal medicine in several Scandinavian countries under national procedures. Safety is generally excellent, but rare anaphylactic reactions have been reported.

Angelica root (Angelicae radix) is a traditional European bitter aromatic herb approved by Commission E for loss of appetite and dyspeptic complaints (mild GI spasms, fullness, flatulence) and by EMA/HMPC for traditional use in mild spasmodic GI complaints and temporary loss of appetite. No ESCOP monograph exists. Its dual mechanism combines bitter-mediated digestive stimulation (via furanocoumarins and bitter principles) with spasmolytic activity from the essential oil components. Angelica root is notably a component of Iberogast (STW 5), the well-studied nine-herb combination product for functional dyspepsia and IBS. As a monotherapy, however, clinical trial evidence is essentially absent. An important safety consideration is the photosensitizing potential of its furanocoumarin content (angelicin, bergapten, imperatorin), and potential interactions with anticoagulant medications.

Arnica is one of Europe's most widely used topical anti-inflammatory herbs, with positive monographs from Commission E, ESCOP, and EMA. Its active sesquiterpene lactones (primarily helenalin) inhibit NF-kB activation and provide genuine anti-inflammatory, analgesic, and anti-edema effects. A landmark 204-patient RCT showed topical arnica gel was non-inferior to 5% ibuprofen gel for hand osteoarthritis. However, internal use is TOXIC (helenalin is a potent cytotoxin), and topical use carries a real risk of allergic contact dermatitis, particularly in individuals sensitive to Compositae (Asteraceae) plants. The distinction between evidence-based topical phytotherapy and homeopathic arnica (highly diluted, different framework) is important.

See full monograph below.

Ashwagandha (Withania somnifera) is a premier Ayurvedic adaptogen whose principal bioactive constituents -- withanolides (withaferin A, withanolide D, and withanolide glycosides) -- modulate the HPA axis, reduce cortisol, and exert GABA-mimetic activity. Two major standardized extracts, KSM-66 and Sensoril, have been evaluated in multiple double-blind RCTs demonstrating significant reductions in perceived stress and anxiety (Chandrasekhar et al. 2012, Salve et al. 2019), improved sleep quality, and modest testosterone-enhancing effects in men. Systematic reviews and meta-analyses (Pratte et al. 2014, Bonilla et al. 2021) confirm a consistent anxiolytic signal, though effect sizes vary by preparation and population. Ashwagandha falls entirely outside the European phytotherapy regulatory framework and carries notable drug interaction potential with thyroid hormones, immunosuppressants, and sedatives.

Astragalus membranaceus is one of the most important herbs in Traditional Chinese Medicine (TCM) for immune support ("tonifying Qi"), with thousands of years of documented use and extensive Chinese-language clinical research. However, it occupies a precarious position in Western evidence-based phytotherapy: it has no Commission E monograph, no ESCOP monograph, no EMA/HMPC monograph, and very limited high-quality Western clinical trial data. The active compounds (astragaloside IV, astragalus polysaccharides, formononetin) have well-characterized immunomodulatory mechanisms in preclinical studies. The herb is very safe even at high doses but lacks the European regulatory infrastructure that characterizes the other herbs in this module. It represents the widest gap between traditional reputation and Western evidence in this collection.

Bacopa monnieri (Brahmi) is a classical Ayurvedic nootropic whose active compounds -- bacosides A and B -- enhance memory and cognitive function through acetylcholinesterase inhibition, serotonin modulation, and BDNF upregulation. Multiple double-blind RCTs in both healthy adults and elderly populations consistently demonstrate improvements in memory acquisition, retention, and cognitive processing speed, with a notable requirement of 8-12 weeks of continuous use before benefits manifest. Bacopa falls outside the European phytotherapy regulatory framework but is listed in the Ayurvedic Pharmacopoeia of India and the Australian TGA.

Baikal skullcap (Scutellaria baicalensis) is one of the 50 fundamental herbs in Traditional Chinese Medicine, where the dried root is known as Huang Qin and has been used for over 2,000 years to "clear heat and drain dampness." The root contains the flavones baicalin, baicalein, and wogonin, which are among the most extensively studied plant-derived anti-inflammatory compounds, demonstrating potent inhibition of NF-kB, COX-2, and 12/15-lipoxygenase pathways as well as broad antiviral activity against influenza, RSV, and SARS-CoV-2. Huang Qin is a key component of the classical formula Xiao Chai Hu Tang (Sho-saiko-to in Japanese Kampo), which has the most substantial clinical trial evidence of any formula containing this herb, particularly for chronic hepatitis. Despite extensive preclinical and pharmacological research, standalone clinical RCT data for Scutellaria baicalensis remains limited; there are no European monographs (Commission E, ESCOP, or EMA/HMPC), though growing Western interest in baicalein as a drug candidate continues to expand the evidence base.

Bearberry (uva ursi) is the traditional European urinary antiseptic, with approval from all major European regulatory bodies for acute uncomplicated lower UTI. Its mechanism is unique: arbutin is converted to hydroquinone, which is excreted in urine and acts as a direct urinary antiseptic -- but only in alkaline urine (pH >7). This pH requirement is a significant practical limitation. Despite strong regulatory support, clinical trial evidence is surprisingly thin, with no published RCTs of bearberry monotherapy vs. antibiotic standard of care. Safety is acceptable but strictly time-limited: maximum 1-2 weeks of use, no more than 5 courses per year, due to hydroquinone's potential hepatotoxicity and theoretical carcinogenicity.

Berberine is an isoquinoline alkaloid found in multiple traditional Chinese and Western medicinal plants, including Coptis chinensis (Huang Lian), Berberis vulgaris (barberry), and Mahonia aquifolium (Oregon grape). Extensive clinical evidence from multiple RCTs and meta-analyses demonstrates significant blood glucose reduction -- comparable to metformin in some head-to-head trials -- alongside clinically meaningful lipid-lowering effects. Its primary mechanism involves AMPK activation and mitochondrial complex I inhibition, with additional effects on gut microbiome modulation (increased Akkermansia and short-chain fatty acid production) and PCSK9 downregulation for cholesterol lowering. Berberine falls outside the European phytotherapy regulatory framework as an isolated alkaloid, though barberry root has some European traditional use history.

Bilberry fruit and its anthocyanin-rich extracts have a dual identity in European phytotherapy. The dried fruit is Commission E-approved for acute nonspecific diarrhea (due to tannin content) and mild oropharyngeal inflammation. The fresh fruit extract, standardized to 25% anthocyanins (as Myrtocyan/Mirtoselect), is used for peripheral vascular insufficiency and capillary fragility, with ESCOP and EMA recognition. Clinical evidence for vascular indications is moderate, with several controlled trials showing improvements in capillary resistance and microcirculation. The popular claim of improved night vision originated from WWII-era anecdotal reports and has not been consistently supported by rigorous trials.

Birch bark extract represents a unique case in phytotherapy: a traditional wound-healing remedy that was developed into a fully EMA-approved pharmaceutical drug through conventional Phase III clinical trials. Episalvan (approved 2016 for partial thickness wounds; withdrawn 2022 for commercial reasons) and Filsuvez (approved EU 2022, FDA 2023 for epidermolysis bullosa) are the same birch triterpene extract (Oleogel-S10). The pivotal EASE trial (n=223) demonstrated significant wound closure benefits in epidermolysis bullosa patients. The active compound betulin promotes keratinocyte differentiation and has anti-inflammatory, antimicrobial, and wound-healing properties. This is the **only herbal extract to achieve full pharmaceutical drug approval for wound healing** in the EU and US.

Birch leaf (Betula pendula/pubescens) is a traditional European diuretic herb used in irrigation therapy for urinary tract conditions. It is approved by Commission E, ESCOP, and EMA/HMPC for irrigation therapy in urinary tract inflammation and renal gravel. The evidence base is predominantly traditional rather than clinical-trial-derived, with EMA granting only "traditional use" status. Active compounds include flavonoid glycosides (particularly hyperoside) and triterpene saponins. Birch leaf is well-tolerated with few adverse effects, but must not be used in patients who require fluid restriction.

Black Cohosh is the best-studied herbal medicine for menopausal vasomotor symptoms in the European phytotherapy tradition. It holds "well-established use" status from the EMA/HMPC, a positive Commission E monograph, and an ESCOP monograph. The primary commercial product, Remifemin (isopropanolic extract, 40 mg/day), has demonstrated efficacy comparable to low-dose conjugated estrogens in some trials. The mechanism is non-estrogenic, acting through serotonergic, dopaminergic, and GABAergic pathways. The hepatotoxicity debate, which generated significant regulatory concern in the mid-2000s, has been largely resolved: rigorous causality assessments found no probable causal link in the vast majority of reported cases, with product adulteration and confounding factors implicated instead.

Black pepper (Piper nigrum) and its alkaloid piperine are used almost exclusively as bioavailability enhancers in modern phytotherapy and supplement practice, not as standalone therapeutics. The landmark finding is a 2000% increase in curcumin blood levels when 20 mg piperine is co-administered. Piperine achieves this through inhibition of P-glycoprotein, CYP3A4, CYP2D6, and glucuronidation enzymes (UGT). However, these same mechanisms create significant drug interaction potential -- piperine at 20 mg/day can increase AUC of simvastatin by 59%, cyclosporine by 35%, and carbamazepine by 48%. No formal herbal monograph exists from Commission E, ESCOP, or EMA for piperine as a bioavailability enhancer. Black pepper occupies a unique position as an adjuvant rather than a primary therapeutic agent.

Boldo is a South American evergreen tree whose leaves have been used traditionally for dyspeptic complaints and mild GI spasms. Commission E approved boldo leaf for dyspepsia and mild spasmodic GI complaints, but neither ESCOP nor the EMA have issued monographs. The primary alkaloid boldine has choleretic and antioxidant properties. Clinical evidence is very limited, consisting mainly of pharmacological studies. The essential oil contains the toxic compound ascaridole and must not be used internally. Caution is warranted with anticoagulant medications due to boldine's antiplatelet effects.

Butcher's Broom (Ruscus aculeatus) is Commission E-approved for supportive therapy of CVI and hemorrhoids. Its active compounds -- the steroidal saponins ruscogenin and neoruscogenin -- have vasoconstrictive and anti-inflammatory effects on venous tissue. The evidence base is smaller than for horse chestnut, with most clinical trials using combination products (ruscus + hesperidin methylchalcone + ascorbic acid). One key multi-center RCT demonstrated significant leg volume reduction. It is a second-line venoactive drug in European phytotherapy.

Butterbur root extract (Petadolex) has some of the strongest clinical evidence of any herbal product for migraine prevention, with Class 1 RCTs showing 48-68% responder rates at 150 mg/day and a former AAN Level A recommendation. However, butterbur plants naturally contain hepatotoxic pyrrolizidine alkaloids (PAs). Although Petadolex is manufactured to be PA-free, reports of liver injury (whose causal relationship to butterbur is disputed) led to product withdrawal in Germany in 2009 and retirement of the AAN guideline. The herb represents a unique case where strong efficacy evidence collides with unresolved safety questions.

Calendula is one of the most widely recognized wound-healing herbs in European phytotherapy, with approval from Commission E, ESCOP, and EMA/HMPC. Its anti-inflammatory and wound-healing activity is primarily attributed to triterpenoid faradiol esters. Clinical trial evidence exists but is limited in quality and quantity, with mixed results across wound types. It has an excellent safety profile for topical use.

California poppy is a mild sedative and anxiolytic herb from the Papaveraceae family that, despite its botanical relationship to the opium poppy, contains no opiate alkaloids. Its active constituents are isoquinoline alkaloids — primarily californidine, eschscholtzine, protopine, and allocryptopine — that interact with GABA-A and benzodiazepine receptors to produce gentle sedative effects. The EMA/HMPC has published a traditional use monograph (EMA/HMPC/680372/2013) for the relief of mild symptoms of mental stress and to aid sleep. No Commission E or ESCOP monograph exists. Clinical trial data are extremely limited; the evidence base rests primarily on long traditional use (over 30 years), preclinical pharmacology demonstrating sedative and anxiolytic properties, and the well-characterized GABA-ergic activity of its alkaloids. It occupies a complementary role alongside valerian, passionflower, and lavender in the Western herbal approach to mild anxiety and sleep disorders.

Topical capsaicin, derived from Capsicum peppers, has the most thoroughly characterized molecular mechanism of any herb in this module: it activates TRPV1 receptors on nociceptive nerve fibers, leading to initial stimulation followed by defunctionalization (not merely "substance P depletion," as was previously taught). It holds EMA "well-established use" status for muscle pain and Commission E/ESCOP approval for musculoskeletal and neuropathic pain. Available in concentrations from 0.025% to 8% (high-concentration prescription patch), it represents a genuine pharmaceutical-grade phytotherapeutic with robust evidence across osteoarthritis, neuropathic pain, and muscular pain.

See full monograph below.

Cat's Claw (Uncaria tomentosa) is a woody vine from the Amazon rainforest with a long history of use in South American indigenous medicine for inflammatory and immune-related conditions. The inner bark contains two chemotypes of oxindole alkaloids -- pentacyclic (POA, considered therapeutic: isopteropodine, mitraphylline) and tetracyclic (TOA, considered antagonistic) -- along with quinovic acid glycosides, procyanidins, and sterols. Limited clinical evidence suggests anti-inflammatory activity in osteoarthritis (one RCT showing benefit for knee OA) and immune-stimulating properties (increased white blood cell count). A Cochrane-style systematic review found insufficient evidence for most claimed indications. Commission E has not issued a monograph, nor has ESCOP, though EMA has not assessed it either. The WHO has published a monograph. Cat's Claw exemplifies a traditional Amazonian remedy with pharmacological plausibility but insufficient clinical trial evidence to support strong therapeutic claims.

Greater celandine was approved by the German Commission E for spastic complaints of the bile ducts and gastrointestinal tract, supported by its rich isoquinoline alkaloid profile (chelidonine, berberine, sanguinarine, coptisine) which exerts papaverine-like spasmolytic and choleretic effects. Limited clinical trial data -- including one placebo-controlled RCT (Ritter 1993) and the Cholagogum F Nattermann biliary dyskinesia trial -- showed modest benefit for functional dyspepsia and upper abdominal pain. However, the herb's risk-benefit profile has been fundamentally altered by reports of idiosyncratic hepatotoxicity (hepatocellular injury pattern, latency 1-6 months), leading to BfArM dose restrictions in Germany, refusal by the EMA/HMPC to adopt a monograph, and a broad reassessment of celandine's place in phytotherapy. Greater celandine also features as a component of STW 5 (Iberogast), the well-studied multi-herb formulation for functional dyspepsia.

Centaury is a European bitter herb from the Gentianaceae family, closely related to gentian, used traditionally for loss of appetite and dyspeptic complaints. Commission E approved it for dyspepsia and loss of appetite, and the EMA granted traditional use status for temporary appetite loss and mild dyspeptic complaints. No ESCOP monograph exists. The herb contains secoiridoid glycosides (swertiamarin, gentiopicroside) that activate bitter taste receptors to stimulate digestive secretions. Clinical evidence is essentially absent; all regulatory approvals are based on pharmacological plausibility and longstanding traditional use. The safety profile is favorable with no known drug interactions.

Chaga (Inonotus obliquus) is a parasitic fungus growing on birch trees in northern latitudes, used in Russian, Scandinavian, and Baltic folk medicine for centuries as a general health tonic, typically prepared as a decoction or tea. The sclerotium contains beta-glucans, betulin and betulinic acid (derived from birch bark), melanin complexes, triterpenoids (inotodiol, lanosterol), and polyphenols with exceptional in vitro antioxidant activity. Preclinical research shows anti-inflammatory, immunomodulatory, and cytotoxic effects, but no human clinical trials have been published for any indication. Despite enormous consumer popularity and marketing claims, chaga has the weakest evidence base of the major medicinal mushrooms. No regulatory body (Commission E, ESCOP, EMA) has assessed it. Evidence rating E reflects traditional use only with no clinical substantiation.

German chamomile is arguably the most comprehensively studied and widely recognized topical anti-inflammatory herb in European phytotherapy. It holds approvals from Commission E, ESCOP, and EMA (including "well-established use" status for some preparations). Active compounds alpha-bisabolol and chamazulene provide demonstrable anti-inflammatory activity. Clinical evidence supports efficacy comparable to low-potency hydrocortisone for eczema. Chamomile has an excellent safety profile, with only rare allergic reactions in Asteraceae-sensitive individuals.

Cinnamon bark has an EMA traditional use monograph for mild GI symptoms (cramping, flatulence). Its use for blood glucose management in type 2 diabetes, while widely marketed, remains clinically inconclusive based on systematic reviews and meta-analyses. A critical distinction exists between cassia cinnamon (high coumarin, more studied for glucose) and Ceylon cinnamon (low coumarin, safer for long-term use but less studied). The European BfR and EFSA have set a tolerable daily intake of 0.1 mg coumarin/kg body weight, which cassia cinnamon can easily exceed.

Coleus forskohlii (syn. Plectranthus barbatus) is an Ayurvedic medicinal plant whose root contains forskolin, the only known natural compound that directly activates adenylyl cyclase, raising intracellular cyclic AMP (cAMP) levels. This universal second messenger mechanism gives forskolin remarkably broad pharmacological effects: bronchodilation, vasodilation, positive cardiac inotropy, lipolysis, reduced intraocular pressure, and anti-inflammatory activity. Clinically, ophthalmic forskolin for glaucoma has the strongest evidence; oral supplementation for body composition and weight management has modest RCT support. Forskolin eye drops are used in some countries as an alternative to beta-blockers for glaucoma. The oral extract (typically standardized to 10-20% forskolin) has shown modest benefits for body composition in small trials. No European regulatory monographs exist, though the plant is documented in the Ayurvedic Pharmacopoeia.

Topical comfrey root extract is one of the best-studied herbal topical treatments for musculoskeletal conditions, with large, well-designed RCTs demonstrating superiority to diclofenac gel for ankle sprains and a 54.7% pain reduction in knee OA. The German product Kytta-Salbe (comfrey root fluid extract ointment) has a robust clinical trial program. However, internal use is ABSOLUTELY CONTRAINDICATED due to hepatotoxic pyrrolizidine alkaloids (PAs), and even topical use is time-limited (4-6 weeks maximum). Modern pharmaceutical products are PA-depleted, making topical use considerably safer than crude preparations, but the PA stigma has overshadowed the genuinely strong topical evidence base.

Cordyceps is a prized tonic fungus from traditional Chinese and Tibetan medicine, historically one of the most expensive medicinal substances in the world due to wild-harvested Ophiocordyceps sinensis scarcity; today it is primarily available as cultivated Cordyceps militaris, which shares a similar active compound profile. The key bioactives -- cordycepin (3'-deoxyadenosine, an adenosine analog) and immunomodulatory beta-glucan polysaccharides -- underpin clinical evidence for improved exercise performance and VO2 max, fatigue reduction, and immune modulation. While small randomized trials support these applications, large-scale confirmatory studies are still needed. Cordyceps falls outside the European phytotherapy regulatory framework.

Cramp bark (Viburnum opulus) is one of the most traditional Western herbal antispasmodics, used primarily for dysmenorrhea (menstrual cramps) and other smooth muscle spasms. It is listed in the British Herbal Pharmacopoeia, the American Herbal Pharmacopoeia, and was included in the United States Pharmacopoeia from 1894 and the National Formulary from 1916. The key compound viopudial, a coumarin unique to V. opulus, provides musculotropic spasmolytic activity on uterine and other smooth muscle, complemented by scopoletin (shared with the related black haw, V. prunifolium). Despite centuries of traditional authority and a coherent pharmacological rationale, virtually no modern clinical trials exist -- making cramp bark one of the starkest examples of the gap between traditional reputation and evidence-based validation. It is generally well-tolerated with a favorable safety profile when the bark (not berries) is used.

Cranberry has the strongest clinical evidence of any urinary herb for UTI prevention, with the 2023 Cochrane update (50 studies, n=8,857) showing a significant 30% reduction in UTI risk (RR 0.70). The mechanism involves proanthocyanidin (PAC) Type A compounds that inhibit E. coli adhesion to urothelial cells. The 36mg/day PAC-A dose has emerged as a standardization target. Unlike most herbs in this collection, cranberry is primarily a North American tradition that has been adopted into European phytotherapy. EMA/HMPC and ESCOP have issued monographs, and it is increasingly recognized by conventional urologists worldwide as a legitimate preventive strategy.

Damiana is a Central and South American shrub with a centuries-old reputation as an aphrodisiac and mood enhancer. The dried leaf has been used in Mexican and Caribbean folk medicine for sexual debility, nervousness, and depression. Phytochemically, damiana contains flavonoids (including pinocembrin and acacetin), cyanogenic glycosides, terpenoids, caffeine, arbutin, and a complex volatile oil. The most pharmacologically interesting finding is dose-dependent PDE-5 inhibition by damiana leaf extracts, suggesting a mechanism analogous to sildenafil for the traditional aphrodisiac claim. However, clinical evidence is extremely limited. A small study in women with sexual interest/arousal disorder showed benefit with a damiana-containing product, but damiana was not isolated as the sole active ingredient. The German Commission E issued a negative monograph, concluding that the evidence was insufficient to establish efficacy for any therapeutic indication. No ESCOP or EMA monograph exists. Safety data is limited; the presence of cyanogenic glycosides raises theoretical toxicity concerns at high doses.

Dandelion is one of the most widely used traditional European medicinal plants, approved by Commission E for disturbances in bile flow, appetite loss, dyspepsia, and stimulation of diuresis. ESCOP recognizes it for restoration of hepatic and biliary function, dyspepsia, and loss of appetite. The EMA grants traditional use status for mild digestive disorders, temporary appetite loss, and increased urine output. Different plant parts have distinct emphasis: the root (Taraxaci radix) is primarily used for hepatobiliary and digestive complaints due to its sesquiterpene lactone and inulin content, while the herb/leaf (Taraxaci herba) is preferred for diuretic effects due to its high potassium content. Clinical trial evidence is very limited; the evidence base rests overwhelmingly on centuries of traditional use, pharmacological plausibility, and the well-characterized choleretic and diuretic properties of its constituents.

Danshen (Salvia miltiorrhiza) is one of the most important cardiovascular herbs in Traditional Chinese Medicine, used for millennia to "activate blood and resolve stasis." The root contains lipophilic tanshinones (tanshinone IIA, cryptotanshinone) and hydrophilic phenolic acids (salvianolic acid B, danshensu) with demonstrated antiplatelet, vasodilatory, antioxidant, and cardioprotective properties. Compound Danshen Dripping Pills (CDDP/T89) is one of the most widely used cardiovascular herbal preparations in China and has undergone FDA Phase III trials for chronic stable angina. Multiple Cochrane reviews cover danshen for acute ischemic stroke and angina, though they consistently note that included Chinese trials have significant methodological limitations. No European regulatory monographs exist. The evidence is moderate -- pharmacologically compelling with extensive Chinese clinical data, but limited by trial quality and the predominance of combination formulas.

Devil's Claw is one of the best-studied herbal anti-inflammatories in the European phytotherapy tradition, with 14+ clinical trials supporting its use in osteoarthritis and low back pain. At doses providing >=50 mg harpagoside daily, it has demonstrated non-inferiority to diacerhein (for OA) and rofecoxib (for low back pain). It is widely prescribed in Germany and France but remains virtually unknown in US clinical practice, representing one of the most significant gaps between European and American phytotherapy.

Dong Quai (Angelica sinensis) is one of the most important herbs in Traditional Chinese Medicine (TCM) for women's health, earning the title "female ginseng." However, from the European evidence-based phytotherapy perspective, it represents the weakest herb in this collection. The EMA/HMPC explicitly REJECTED adoption of a monograph due to inadequate evidence of 30+ years of use in the EU, toxicological concerns, and the need for medical supervision. There is no Commission E monograph. The only major RCT as a standalone treatment (Hirata 1997, n=71) showed no benefit over placebo for menopausal symptoms. Significant safety concerns exist regarding anticoagulant interactions (documented potentiation of warfarin) and photosensitivity due to coumarin and furanocoumarin content. Dong Quai represents the largest gap between traditional reputation and evidence-based validation in this collection.

Echinacea is the most extensively studied herbal immunomodulator, with 20+ RCTs and a Cochrane review. However, the clinical evidence remains frustratingly heterogeneous because different species, plant parts, and preparation types have been tested. European regulators have addressed this by issuing separate monographs for each species/part combination. E. purpurea aerial parts (fresh pressed juice) have the strongest European endorsement and most clinical data. The Cochrane review concludes that some Echinacea products may reduce cold incidence and duration, but the evidence is not definitive. Commission E approved E. purpurea herb, E. purpurea root, and E. pallida root for different indications.

Echinacea's topical wound-healing application is a well-established tradition in German phytotherapy that is nearly invisible in the Anglophone world. Commission E approves external use for poorly healing wounds and chronic ulcerations. The EMA/HMPC classifies topical echinacea for small superficial wounds as "traditional use." The primary commercial product is Echinacin Madaus ointment (Germany). A large uncontrolled study (n=4,598) reported an 85% success rate for various wounds, burns, and inflammatory skin conditions. However, the evidence base is weak by modern standards -- primarily traditional use documentation and uncontrolled studies, with no published high-quality RCTs for topical wound healing. Active compounds include alkamides, caffeic acid derivatives, and polysaccharides.

Elderberry (Sambucus nigra fruit) has some of the most compelling clinical trial data of any herbal immunomodulator for acute respiratory viral infections, with a meta-analysis showing a large effect size (d=1.717) for reducing duration of upper respiratory symptoms. The key Zakay-Rones 2004 trial showed influenza recovery in 3-4 days vs. 7-8 days for placebo. Despite this, the EMA/HMPC declined to issue a monograph for elderberry fruit (while accepting elderflower) because documentation of 30-year traditional medicinal use at a specified dosage was deemed insufficient. This regulatory gap highlights the sometimes arbitrary nature of the EU traditional use framework. Elderberry is generally very safe with a favorable risk-benefit profile.

Elderflower (Sambucus nigra flos) is one of the oldest European diaphoretic remedies for feverish colds. Commission E approves the flowers for common cold. The strongest modern clinical evidence is actually for elderberry (the fruit), not the flower, with a meta-analysis showing large effect sizes for reducing upper respiratory symptoms. Elderflower's traditional role as a diaphoretic ("sweat cure" herb) and its inclusion in the Sinupret combination product are its most important contemporary uses. Clinical trial data specifically for elderflower monotherapy is limited.

Eleuthero (Eleutherococcus senticosus) occupies a historically important but evidentially awkward position in phytotherapy. It was the subject of extensive Soviet-era research by Brekhman and colleagues who coined the modern concept of "adaptogens," and it received a positive Commission E monograph in Germany -- one of only a handful of herbs formally recognized as adaptogens by any Western regulatory body. The EMA/HMPC also adopted a monograph (2008) for "symptoms of asthenia such as fatigue and weakness." However, modern systematic reviews consistently find that the clinical evidence is heterogeneous, of low quality, and insufficient to make strong efficacy claims by current standards. The herb is very safe, with no significant toxicity even at high doses, and has a well-characterized phytochemical profile (eleutherosides). It is a component of the Kan Jang product (with Andrographis) for URTI treatment. The EU-US divergence is notable: regulatory recognition in Europe but minimal cl

Eucalyptus oil and its principal monoterpene component 1,8-cineole are well-established in European phytotherapy for respiratory catarrh, bronchitis, sinusitis, and as adjunctive therapy in COPD and asthma. The isolated compound 1,8-cineole (available as Soledum capsules in Germany) has stronger and more specific clinical evidence than crude eucalyptus oil preparations. Multiple clinical trials demonstrate anti-inflammatory effects, mucolytic activity, and steroid-sparing potential. Commission E and ESCOP both approve eucalyptus oil for respiratory catarrh.

Evening Primrose Oil is one of the most widely used supplements for women's health, particularly for PMS and cyclical mastalgia. However, there is a notable gap between its consumer popularity and the strength of clinical evidence. The EMA/HMPC has granted only "traditional use" status, and only for dry skin conditions -- not for PMS or mastalgia. The active compound is gamma-linolenic acid (GLA), an omega-6 fatty acid precursor to anti-inflammatory prostaglandins. While some individual trials show positive results for mastalgia and PMS, systematic reviews and meta-analyses present mixed findings. The Cochrane review found insufficient evidence for atopic dermatitis. EPO represents a case where traditional reputation and consumer demand have outpaced scientific validation.

See full monograph below.

Fenugreek seed is one of the oldest medicinal plants, approved by Commission E for internal use (loss of appetite) and external use (local inflammation as poultice). The ESCOP monograph additionally includes adjuvant therapy in diabetes and mild hypercholesterolemia. The EMA/HMPC recognizes traditional use for appetite loss (internal) and mild skin inflammations (external). Clinical evidence for blood glucose reduction in type 2 diabetes is positive in meta-analyses (significant reductions in fasting glucose and HbA1c) but based largely on low-quality trials. A distinctive maple-syrup odor in sweat and urine is a harmless but notable side effect.

Feverfew is one of the most studied herbal medicines for migraine prevention, approved by the German Commission E and included in ESCOP monographs for this indication. The key active constituent, parthenolide (a sesquiterpene lactone), inhibits serotonin release from platelets, blocks NF-kB activation, and desensitizes TRPA1 channels in the trigeminovascular system. The 2012 AAN/AHS guideline classified the standardized CO2 extract MIG-99 as "probably effective" (Level B) for migraine prophylaxis, based on one positive Class I and one positive Class II trial. However, evidence across studies remains mixed -- a 2015 Cochrane review concluded there is only low-quality evidence overall -- and the EMA/HMPC has classified feverfew only under "traditional use" rather than "well-established use" for migraine prevention.

Boswellia serrata (Indian frankincense) is an increasingly important anti-inflammatory herb with a growing evidence base in osteoarthritis, particularly knee OA. Its unique mechanism -- dual inhibition of 5-LOX and NF-kB, distinct from the COX pathway targeted by NSAIDs -- makes it a complementary rather than duplicative therapeutic option. Multiple RCTs with proprietary extracts (5-Loxin, Aflapin) show significant improvements in pain and function, with onset as early as 7 days. However, unlike most other herbs in this module, Boswellia lacks a full EMA herbal monograph, and its European regulatory position is less developed than its Ayurvedic tradition and modern clinical evidence would warrant.

Fumitory is a Commission E-approved herb for colicky pain of the gallbladder, biliary system, and gastrointestinal tract. Its key alkaloid protopine exhibits a distinctive amphocholeretic effect, meaning it normalizes bile flow by increasing low bile secretion and decreasing excessive bile production. Fumitory is one of the traditional European "bitter" cholagogues with a history of use stretching back to Dioscorides and Galen. ESCOP and the EMA/HMPC also recognize its use for hepatobiliary digestive complaints, though the EMA limits it to traditional use status. Despite centuries of use and regulatory recognition, modern clinical trial evidence remains very limited, consisting of small, older studies. The herb is generally well tolerated at recommended doses.

Garlic is Commission E-approved for supportive treatment of elevated blood lipids and prevention of age-dependent vascular changes. Meta-analyses of older trials showed approximately 12% reductions in total cholesterol with garlic powder (600-900 mg/day), but more recent high-quality trials have shown more modest effects. The most compelling cardiovascular evidence comes from a 4-year study showing significant inhibition of atherosclerotic plaque progression. Garlic has an excellent safety profile but interacts with anticoagulants and CYP450 substrates.

See full monograph below.

See full monograph below.

Ginger is one of the few herbal medicines to receive EMA "well-established use" classification -- for prevention of nausea and vomiting in motion sickness. This is the highest regulatory recognition in EU phytotherapy, supported by multiple RCTs and meta-analyses. Evidence for pregnancy-related nausea is positive but European regulatory bodies remain cautious (Commission E and ESCOP do not endorse this use). Post-operative nausea evidence is growing. Ginger's safety profile is excellent at recommended doses, making it one of the most evidence-based herbs in this module.

Ginkgo biloba, specifically the standardized extract EGb 761 (Tebonin/Tanakan), has strong evidence for the symptomatic treatment of mild-to-moderate dementia and mild cognitive impairment at 240 mg/day, with meta-analyses confirming significant improvements in cognition, neuropsychiatric symptoms, activities of daily living, and quality of life. However, two landmark mega-trials (GEM: n=3,069; GuidAge: n=2,854) conclusively demonstrated that EGb 761 does NOT prevent the development of dementia in elderly individuals. Tinnitus evidence is mixed: EGb 761 appears to help tinnitus as a concomitant symptom of dementia but NOT as a standalone primary condition. The bleeding risk historically associated with ginkgo appears to be overstated based on current controlled trial evidence. The EMA grants "well-established use" status for age-related cognitive impairment.

Goji berry (Lycium barbarum) is one of the most important tonic herbs in Traditional Chinese Medicine (Gou Qi Zi), used for over 2,000 years to nourish Liver and Kidney yin, replenish Jing (essence), and brighten the eyes. Lycium barbarum polysaccharides (LBP), comprising 5-8% of the dried fruit, are the primary bioactive fraction with well-characterized immunomodulatory, antioxidant, and neuroprotective effects through activation of macrophages, dendritic cells, NK cells, and T lymphocytes via TLR2/TLR4-NF-kB signaling. The fruit is also among the richest dietary sources of zeaxanthin (as zeaxanthin dipalmitate, 0.5-1.2 mg/g dry weight), and two randomized trials have demonstrated increased macular pigment optical density with daily goji berry intake. Limited but growing clinical evidence supports benefits for immune enhancement, general wellbeing, and in vivo antioxidant status, though most trials are small and short-term. A clinically important warfarin interaction has been documented in multiple case reports, mediated by CYP2C9 inhibition, causing markedly elevated INR and bleeding. Goji berry has no European regulatory monographs (Commission E, ESCOP, or EMA/HMPC).

European goldenrod (Solidago virgaurea) is the flagship herb of European irrigation therapy ("Durchspuelungstherapie") -- a uniquely European therapeutic concept involving copious fluid intake combined with diuretic/anti-inflammatory herbs to flush the urinary tract. It holds positive assessments from all three major European regulatory bodies (Commission E, ESCOP, EMA/HMPC) for urinary tract inflammation, renal gravel, and adjunctive treatment of bacterial UTIs. Its pharmacology combines diuretic, anti-inflammatory, spasmolytic, and mild analgesic effects. Clinical trial evidence is limited, but pharmacological studies and long traditional use form a coherent rationale.

Gotu kola (Centella asiatica) is notable for bridging Western phytotherapy and Ayurvedic traditions. In European medicine, its primary evidence-based application is chronic venous insufficiency (CVI), where the standardized Total Triterpenic Fraction of Centella asiatica (TTFCA, containing asiaticoside, madecassoside, asiatic acid, madecassic acid) has demonstrated significant improvements in venous tone, capillary permeability, and microcirculation in multiple controlled trials. It also has well-documented wound-healing and scar-reduction properties. The EMA/HMPC has granted traditional use status for heavy legs related to venous disturbances and minor wound healing. Commission E and ESCOP have not issued monographs, reflecting a gap between the existing clinical evidence and formal European regulatory recognition.

Grape seed extract (GSE) is a concentrated source of oligomeric proanthocyanidins (OPCs), typically standardized to 95% or greater OPC content. Meta-analyses of RCTs demonstrate modest but consistent blood pressure reductions, particularly for diastolic blood pressure (-2.2 mmHg) and heart rate (-1.25 bpm), with benefits most pronounced in younger, obese, or metabolically compromised individuals. The primary mechanism involves enhanced endothelial nitric oxide synthase (eNOS) expression and increased nitric oxide production, leading to vasodilation and improved endothelial function. Additional evidence supports use in chronic venous insufficiency and as a systemic antioxidant. No European regulatory body (Commission E, ESCOP, EMA) has published a monograph specifically for grape seed, though the EMA has a monograph for Vitis vinifera leaf (a different plant part used as Red Vine Leaf). GSE is distinct from Red Vine Leaf extract both botanically (seed vs leaf) and in its evidence profile. The clinical evidence is moderate in quality -- multiple independent research groups have contributed, but studies remain generally small and short-term.

Green tea (Camellia sinensis) and its principal catechin EGCG have moderate-to-strong evidence for modest improvements in cardiovascular risk factors, with meta-analyses of 31+ RCTs demonstrating reductions in LDL cholesterol (~4.5 mg/dL), total cholesterol (~4.7 mg/dL), and systolic blood pressure (~2 mmHg). Evidence for weight management is consistent but effect sizes are small (approximately 1 kg over 12 weeks). Cancer prevention data from pooled observational studies suggest a 9% risk reduction (RR 0.91), though individual RCTs have shown mixed results. The EFSA identified 800 mg/day of EGCG from supplements as a threshold above which hepatotoxicity risk increases, distinguishing the safety profile of concentrated extracts from traditional green tea infusions. The EMA/HMPC grants traditional use status for symptoms of fatigue and asthenia.

Gymnema sylvestre is a woody climbing vine from the Apocynaceae family, used for over 2,000 years in Ayurvedic medicine under the name "Meshashringi" (sugar destroyer) for glycosuria and metabolic disorders. Its primary bioactives, gymnemic acids I-VII, structurally resemble glucose and block sweet taste receptors on the tongue (T1R2/T1R3) while inhibiting intestinal glucose absorption. A 2021 systematic review and meta-analysis of 10 studies (n=419) found significant reductions in fasting blood glucose, postprandial glucose, and HbA1c in type 2 diabetes patients, though most trials were small, open-label, and of low-to-moderate methodological quality. Animal studies suggest possible pancreatic beta-cell regeneration, but this remains unconfirmed in humans. No European regulatory body (Commission E, ESCOP, or EMA) has issued a monograph for gymnema, limiting its formal recognition to the Indian Pharmacopoeia and Ayurvedic Pharmacopoeia of India.

Hawthorn extract WS 1442 is the most rigorously studied herbal cardiac medicine. It has Commission E approval for NYHA II heart failure, ESCOP and EMA/HMPC monograph support, and was tested in a 2,681-patient mortality trial (SPICE). While the SPICE trial did not meet its primary endpoint, it demonstrated excellent safety alongside optimal heart failure medication and showed a significant reduction in sudden cardiac death in the NYHA III subgroup. The mechanism involves positive inotropy without increased myocardial oxygen demand -- a unique pharmacological profile among cardiac agents.

Hibiscus (roselle) calyx tea is one of the better-studied herbal interventions for mild-to-moderate hypertension. Multiple RCTs and meta-analyses show significant reductions in systolic blood pressure (approximately 7 mmHg) and diastolic blood pressure (approximately 4 mmHg) compared to placebo. The anthocyanins delphinidin-3-sambubioside and cyanidin-3-sambubioside appear to act via ACE inhibition and endothelial nitric oxide synthase upregulation. Despite this growing evidence base, hibiscus has no Commission E, ESCOP, or EMA monograph. It is widely consumed as a traditional beverage (karkade) across Africa, the Middle East, and Latin America. The safety profile is favorable, with minor GI disturbances as the main side effect, though potential interactions with antihypertensive medications (particularly ACE inhibitors and diuretics) warrant caution.

Holy basil (Ocimum tenuiflorum), known as Tulsi or "The Incomparable One" in Ayurveda, is a sacred adaptogenic herb with growing clinical evidence for stress reduction, anxiolytic effects, and metabolic benefits including blood glucose and lipid modulation. Its multi-target mechanism involves cortisol modulation via HPA axis regulation, eugenol-mediated COX-2 inhibition, and broad-spectrum antioxidant activity through rosmarinic acid and other phenolic compounds. Several small RCTs support its adaptogenic and metabolic claims, though larger confirmatory trials are needed. It falls outside the European phytotherapy regulatory framework entirely.

Hops is one of the oldest European sedative herbs, with the female flower cones (strobiles) used medicinally. It is almost never studied or used alone for sleep -- instead, it is nearly always combined with valerian, and this combination has its own EMA/HMPC monograph. The sedative mechanism involves GABA modulation via bitter acid degradation products (particularly 2-methyl-3-buten-2-ol), and possibly melatonin receptor activity. Standalone clinical evidence is very weak, consisting primarily of studies using very low doses in non-alcoholic beer. The valerian-hops combination has somewhat better evidence, though still modest. Hops is very safe with virtually no adverse effects at recommended doses.

Horse chestnut seed extract (HCSE) standardized to aescin (escin) has the strongest evidence base of any herbal treatment for chronic venous insufficiency (CVI). A Cochrane review of 17 RCTs found consistent significant reductions in leg pain, edema, and leg volume. In some trials, HCSE was comparable to compression stockings. It is approved by Commission E, has ESCOP and EMA/HMPC monographs, and is widely prescribed in Germany. In the US, CVI is an undertreated condition and HCSE is virtually unknown to mainstream physicians.

Horsetail (Equisetum arvense) is a traditional European diuretic herb used in irrigation therapy for urinary tract conditions. One notable RCT (Carneiro 2014, n=36) showed diuretic effect equivalent to hydrochlorothiazide 25mg without electrolyte disturbance -- a significant finding if confirmed. EMA/HMPC grants traditional use status. The herb is distinctive for its exceptionally high silica content (up to 10% of dry weight), which also supports its traditional use for connective tissue strengthening. Evidence quality is preliminary due to limited clinical trials.

See full monograph below.

Iceland Moss (Cetraria islandica) is a lichen -- not a true moss -- with a long history in Nordic and Central European herbal medicine as a demulcent for dry coughs, sore throats, and upper respiratory irritation. Commission E approved it for loss of appetite and catarrhs of the upper respiratory tract, and EMA grants traditional use status for dry cough and oral/pharyngeal irritation as well as temporary appetite loss. The key active constituents are polysaccharides (lichenin, isolichenin) that form a soothing mucilaginous layer on irritated mucous membranes, along with bitter lichen acids (usnic acid, fumarprotocetraric acid) that stimulate appetite. Despite centuries of use in Scandinavian and Alpine folk medicine, virtually no modern clinical trial evidence exists. It remains a well-regarded traditional remedy in European pharmacy, particularly in cough lozenges and throat teas.

Ivy leaf extract is one of the best-evidenced herbal expectorants in European phytotherapy. The standardized extract EA 575 (marketed as Prospan) has been studied in over 65,000 patients across clinical and observational studies. It has a well-characterized molecular mechanism involving indirect beta-2 adrenergic receptor stimulation via the saponin alpha-hederin. It holds approvals from all three major European regulatory bodies (Commission E, ESCOP, EMA/HMPC) and is widely used in pediatric practice.

Java tea (Orthosiphon stamineus) is a Southeast Asian plant that has become an established European phytomedicine for urinary tract irrigation therapy ("Durchspuelungstherapie"). Commission E approves it for irrigation in bacterial and inflammatory diseases of the lower urinary tract and for urinary gravel. EMA grants traditional use status for increasing urine volume as adjuvant in minor urinary complaints. The leaves contain polymethoxylated flavonoids (sinensetin, eupatorin), rosmarinic acid, high potassium salt content, and diterpenes (orthosiphol). The diuretic (aquaretic) effect is well-documented pharmacologically, with the potassium salts and flavonoids contributing to increased urine output without significant electrolyte depletion. Clinical trial evidence is limited, consisting primarily of older pharmacological studies and small observational trials. ESCOP has not issued a monograph.

Jujube (Ziziphus jujuba) is one of the most important sedative and calming herbs in Traditional Chinese Medicine, where the seed (Suan Zao Ren) is the primary part used for insomnia and anxiety, and the fruit (Da Zao) serves as a harmonizing agent in numerous classic formulas. The seed contains jujubosides (dammarane-type saponins), spinosin (a C-glycoside flavonoid), and sanjoinine alkaloids with demonstrated GABAergic and serotonergic activity in preclinical studies. Suan Zao Ren Tang, a classical TCM formula containing jujube seed as the principal herb, is one of the most commonly prescribed insomnia treatments in China, Taiwan, and Japan (Kampo: Sansoninto). Limited clinical trials show modest sleep quality improvements, but methodological quality is generally poor. No European regulatory monographs exist. The evidence rating is low, with pharmacological plausibility but insufficient clinical substantiation by Western standards.

Juniper berry (Juniperus communis) is approved by the German Commission E for dyspeptic complaints and by ESCOP for improvement of renal water excretion. It has a centuries-long tradition in European phytotherapy as a urinary tract support herb and mild aquaretic/diuretic. The essential oil is rich in monoterpenes -- primarily alpha-pinene (20-50%), myrcene, sabinene, and terpinen-4-ol -- the latter considered chiefly responsible for the aquaretic effect via increased glomerular filtration rate. Despite strong traditional documentation and plausible pharmacology, modern clinical trial evidence remains very limited. Nephrotoxicity concerns exist at high doses or with prolonged use exceeding four weeks, and juniper is strictly contraindicated in pregnancy and kidney disease.

Kava is one of the best-studied herbal anxiolytics, with a positive Cochrane review (12 RCTs, n=700) and robust evidence from the standardized extract WS 1490. Its anxiolytic effects are mediated through GABA-A potentiation, monoamine reuptake inhibition, and sodium channel modulation, providing anxiolysis without the sedation or cognitive impairment of benzodiazepines. However, the herb's regulatory history is dominated by a hepatotoxicity scare beginning in 1999 that led to market withdrawal in Germany (2002) and across much of the EU. Subsequent analysis strongly suggests the liver injury cases were largely attributable to poor-quality plant material (tudei kava instead of noble kava), inappropriate extraction methods (acetone instead of ethanol or water), use of non-root plant parts, and possibly idiosyncratic/immunoallergic reactions. A German court overturned the ban, but it was reimposed in 2019, despite ongoing scientific criticism of the regulatory reasoning.

Silexan (Lasea) is a proprietary standardized oral lavender oil preparation (80 mg/day) that has emerged as one of the best-evidenced herbal anxiolytics. Five major RCTs (n=1,213 for the placebo comparisons) demonstrate efficacy comparable to lorazepam 0.5 mg/day and paroxetine 20 mg/day for generalized anxiety disorder, with a superior safety profile (non-sedating, no abuse potential, no dependence). Its mechanism is novel: inhibition of voltage-gated calcium channels (primarily T-type and N-type), similar in concept to pregabalin but with a different binding site and without sedation. Recent data (2024) also suggest efficacy in mild-to-moderate depression. The EMA/HMPC has registered Silexan as a traditional herbal medicine for temporary anxiety in patients aged 12+.

Lemon balm is a versatile medicinal herb in the European tradition with three distinct therapeutic profiles: (1) internal use for mild anxiety and sleep disturbance (traditional use, moderate evidence), (2) cognitive enhancement via acetylcholinesterase inhibition (emerging evidence, relevant to Alzheimer's), and (3) topical antiviral activity against herpes simplex (good clinical evidence from RCTs). Its mechanism involves modulation of GABAergic, cholinergic, and serotonergic systems, with rosmarinic acid as the principal bioactive constituent. The EMA/HMPC approved it in 2013 as a traditional medicine for mild mental stress, sleep support, and mild GI complaints. It has an excellent safety profile.

Licorice root is one of the most important herbs in both European and Asian medicine, approved by Commission E and ESCOP for gastric/duodenal ulcers, gastritis, and respiratory catarrh. Its primary active compound glycyrrhizin (and its metabolite glycyrrhetinic acid) has potent anti-inflammatory and mucosal-protective effects but also causes mineralocorticoid-like adverse effects: sodium retention, potassium loss, and hypertension. This limits use to 4-6 weeks and a maximum glycyrrhizin intake of 100 mg/day. DGL (deglycyrrhizinated licorice) was developed to provide GI benefits without the hypertension risk and is effective for peptic ulcer symptoms when taken as chewable tablets.

Linden flower (Tiliae flos) is one of the most traditional European remedies for feverish colds, used for centuries as a diaphoretic "sweat cure" herb. It has Commission E, ESCOP, and EMA/HMPC approval, but its evidence base is almost entirely from traditional use rather than clinical trials. No meaningful modern RCTs exist. Its diaphoretic mechanism is attributed to flavonoids (quercetin, kaempferol) and phenolic acids. It remains very popular as a home remedy tea in German-speaking countries. There is a notable safety concern: the German Commission E monograph mentions potential cardiotoxicity, though this is contested and may apply only to excessive doses.

See full monograph below.

Lion's Mane (Hericium erinaceus) is a medicinal mushroom with a long history of use in traditional Chinese and Japanese medicine, now attracting significant scientific interest for its unique neurotrophic properties. Its key bioactive compounds -- hericenones (from the fruiting body) and erinacines (from the mycelium) -- stimulate the synthesis of nerve growth factor (NGF), a mechanism distinct from all conventional nootropics. The landmark Mori et al. 2009 RCT demonstrated significant cognitive improvement in patients with mild cognitive impairment over 16 weeks, though benefits reversed upon discontinuation. Preclinical evidence for neuroprotection and remyelination is strong, but clinical trial data remains limited in both quantity and sample size. Lion's Mane falls outside the European phytotherapy regulatory framework.

Lovage root (Levisticum officinale) is a traditional European medicinal herb approved by the German Commission E for irrigation therapy in urinary tract inflammation and prevention of kidney gravel, and by the EMA/HMPC for traditional use as an aquaretic in minor urinary complaints. It is best known today as a key component of Canephron N (Bionorica), one of the most widely prescribed urological phytopharmaceuticals in Europe, which combines lovage root with rosemary leaves and centaury herb. While standalone clinical evidence for lovage root is limited, the combination product has been evaluated in a Phase III non-inferiority trial against fosfomycin for uncomplicated UTIs (PMID: 30231252). The root's pharmacology centers on phthalides (ligustilide, butylphthalide) and essential oil constituents that confer aquaretic, spasmolytic, and anti-inflammatory effects.

Maca (Lepidium meyenii) is a Peruvian Andean root vegetable cultivated above 4000m altitude, traditionally used for energy, stamina, and fertility. Clinical trials -- most notably Gonzales et al. (2002) -- demonstrate improved sexual desire and libido in both men and women, with some evidence supporting enhanced spermatogenesis. Uniquely, maca does not directly alter sex hormone levels (testosterone, estradiol, FSH, LH), suggesting a non-hormonal mechanism of action possibly involving the endocannabinoid system. It has also been studied for menopausal symptoms, exercise performance, and SSRI-induced sexual dysfunction. Maca falls outside the European phytotherapy regulatory framework but holds EU novel food status.

Magnolia bark (Magnolia officinalis) is a traditional Chinese medicine herb whose key bioactive compounds -- honokiol and magnolol -- act as positive allosteric modulators of GABA-A receptors, providing anxiolytic and mild sedative effects. Preclinical evidence is strong and mechanistically compelling, but clinical data is limited primarily to the proprietary Relora combination product (Magnolia + Phellodendron). Evidence suggests benefits for stress-related anxiety, cortisol reduction, and sleep quality, though standalone magnolia bark RCTs are lacking. It falls outside the European phytotherapy regulatory framework entirely.

Marshmallow root is one of the oldest and most respected demulcent herbs in European phytotherapy, specifically indicated for dry irritative cough and mucous membrane irritation. It holds Commission E, ESCOP, and EMA/HMPC approval. Its mechanism -- bio-adhesive mucilage polysaccharides forming a protective film on irritated mucosa -- is well-understood and pharmacologically elegant. Clinical evidence includes a large consumer survey (n=822) demonstrating rapid symptom relief, but large placebo-controlled RCTs are lacking. The standardized extract STW 42 (Phytohustil) is the most studied preparation.

Meadowsweet (Filipendula ulmaria) is historically significant as the plant from which aspirin derived its name -- "a-spirin" from "Spiraea," the old genus name for meadowsweet. The flowers and aerial parts contain salicylaldehyde, methyl salicylate, and salicin, along with flavonoids (notably spiraeoside) and tannins (rugosins). It holds EMA traditional use status for supportive treatment of common cold and as adjuvant for mild joint pain, but lacks Commission E or ESCOP monographs. No clinical trials exist for meadowsweet monotherapy. Paradoxically, despite its salicylate content, meadowsweet has been traditionally used to soothe the stomach -- in contrast to aspirin's well-known gastric irritation. This gastroprotective effect is attributed to its tannin and mucilage content, which may buffer the salicylate effects. Drug interactions with NSAIDs and anticoagulants are possible due to salicylate content.

See full monograph below.

European mistletoe is one of the most widely used complementary cancer therapies in German-speaking countries (~77% of oncology patients), administered as subcutaneous injections of standardized extracts (Iscador, Helixor, abnobaVISCUM). It contains immunomodulatory lectins and cytotoxic viscotoxins. Clinical evidence suggests improvements in quality of life and possible survival benefits, but the evidence base is methodologically contested. The US FDA has not approved mistletoe for any indication and prohibits its importation except for research. This is the single largest EU-US divergence in complementary medicine.

Moringa (Moringa oleifera) is a fast-growing tropical tree called the "Miracle Tree" due to its exceptional nutritional density -- the leaves contain all essential amino acids, significant vitamins (A, C, E, B-complex), minerals (calcium, iron, potassium), and bioactive compounds including isothiocyanates (moringin), flavonoids (quercetin, kaempferol), and phenolic acids (chlorogenic acid). Clinical trials, mostly small, show promising effects on blood glucose regulation, lipid profiles, and inflammatory markers. The isothiocyanate moringin activates Nrf2 antioxidant pathways and shows immunomodulatory activity. No European regulatory monographs exist, though moringa is extensively documented in Ayurveda and is recognized as a significant medicinal plant by the WHO for nutritional applications in developing countries. Evidence is moderate -- nutritional benefits are well-established, but clinical evidence for specific therapeutic claims remains limited by small sample sizes.

Mucuna pruriens seeds are one of the richest natural sources of L-DOPA (levodopa, 3-6% by weight), the immediate precursor to dopamine and the gold-standard treatment for Parkinson's disease. Small clinical trials (total ~108 participants) have shown that Mucuna seed powder produces comparable motor improvements to synthetic levodopa/carbidopa, with potentially faster onset and longer "on" time without increased dyskinesia. However, long-term tolerability is a concern, with 50% of patients in one study discontinuing due to GI side effects or motor worsening. Separate evidence from Ayurvedic tradition and clinical studies supports use for male infertility, where 5 g/day seed powder for 3 months improved sperm parameters and reproductive hormones in infertile men. Known in Ayurveda as Kapikacchu, it is classified as a Vajikara (aphrodisiac) and nervine tonic. No Commission E, ESCOP, or EMA monograph exists. Self-treatment of Parkinson's disease with Mucuna is strongly discouraged without medical supervision due to the need for precise L-DOPA dosing.

Mullein flower (Verbasci flos) is a traditional European demulcent and expectorant herb used for centuries in the treatment of respiratory catarrh and cough. It holds Commission E approval for catarrhs of the respiratory tract and EMA traditional use registration as an expectorant in cough associated with cold, but is not covered by ESCOP. Its mucilage content (approximately 3%) provides a soothing demulcent effect on irritated mucous membranes, while saponins (verbascosaponin) contribute a mild expectorant action. Clinical trial evidence is essentially absent; approval rests almost entirely on longstanding traditional use and pharmacological plausibility. Mullein is frequently used in combination with other respiratory herbs such as thyme and marshmallow in European herbal tea blends.

Myrtol standardized (ELOM-080, marketed as GeloMyrtol forte) is a unique phytopharmaceutical consisting of a defined essential oil distillate with standardized content of three monoterpenes: 1,8-cineole, d-limonene, and alpha-pinene. It has strong RCT evidence for both acute sinusitis and acute bronchitis, with a landmark trial showing efficacy comparable to the antibiotic cefuroxime and the mucolytic ambroxol. It is one of the best-selling OTC respiratory medicines in Germany. Its multi-target mechanism includes secretolytic, mucolytic, anti-inflammatory, antimicrobial, and bronchospasmolytic effects.

Neem is one of the most versatile and widely used medicinal plants in Ayurveda, where it is known as Nimba and valued for its bitter, cooling properties. Virtually every part of the tree is used medicinally -- leaves, bark, seeds, flowers, and twigs. The principal bioactive compound is azadirachtin, alongside nimbidin, nimbin, nimbolide, quercetin, and gedunin. In vitro and animal studies demonstrate potent antimicrobial, anti-inflammatory, antifungal, and insecticidal activities. Traditional use for skin diseases, oral health (neem twig chewing sticks), and as a blood purifier is well-documented across South Asia. However, clinical trial evidence meeting Western standards is very limited, and no European regulatory body (Commission E, ESCOP, or EMA) has issued a monograph. The WHO Monographs on Selected Medicinal Plants includes neem leaf. Safety concerns exist particularly for neem oil ingestion, which has been associated with serious adverse effects in children.

Nettle root is a well-established European BPH herb with moderate clinical evidence, most commonly used in combination with saw palmetto (PRO 160/120 / Prostagutt forte). Its mechanism involves SHBG binding inhibition, aromatase inhibition, and anti-inflammatory effects. Commission E and ESCOP approve it for BPH stages I-II, but EMA/HMPC has only granted "traditional use" status, reflecting that confirmatory large-scale RCTs are still lacking. An excellent safety profile supports its use as a long-term adjunct therapy.

Nigella sativa (black seed) is a traditional medicinal plant whose principal bioactive constituent, thymoquinone, has demonstrated cardiovascular-relevant pharmacological activity including antioxidant, anti-inflammatory, calcium channel blocking, and ACE-inhibitory effects. A 2025 GRADE-assessed meta-analysis of 82 RCTs (n=5,026) found statistically significant reductions in systolic blood pressure (~3 mmHg), diastolic blood pressure (~2.7 mmHg), total cholesterol, LDL-cholesterol, and triglycerides with Nigella sativa supplementation, though effect sizes are modest and clinical significance is uncertain. Evidence quality is limited by heterogeneous methodology, small sample sizes, and variable extract standardization. No European regulatory body (Commission E, ESCOP, EMA/HMPC) has issued a monograph for Nigella sativa. The seed is FDA GRAS for food use and generally well tolerated at doses up to 3 g/day, but has potential interactions with warfarin, antihypertensives, and hypoglycemic agents via CYP2C9 and CYP3A4 inhibition.

Oat Straw (Avena sativa) refers to the aerial parts of the common oat plant, harvested either as green milky oats (Avenae herba) or as dried straw (Avenae stramentum), with a long tradition in European herbal medicine as a mild nervine tonic and bath additive. Commission E approved oat straw for external use only (baths for inflammatory and seborrheic skin conditions), while EMA grants traditional use status for mild mental stress relief and for skin complaints (bath). A proprietary green oat extract (Neuravena) has shown modest cognitive benefits in healthy adults in a few small RCTs. The key constituents include avenanthramides (unique polyphenolic antioxidants), flavonoids (vitexin, isovitexin), saponins (avenacosides), and beta-glucans. Despite the widespread folk reputation as a nervous system tonic ("sowing wild oats"), the clinical evidence base remains limited.

Olive leaf extract (Olea europaea L., folium) is an emerging antihypertensive herbal medicine with roots in Mediterranean traditional medicine. The landmark Susalit 2011 trial (n=232) demonstrated that olive leaf extract (500 mg twice daily, equivalent to ~200 mg oleuropein/day) was non-inferior to captopril 12.5-25 mg twice daily for stage-1 hypertension over 8 weeks. The mechanism involves ACE inhibition via oleuropein and oleacein. While the EMA/HMPC has published a monograph on olive leaf, it is for "traditional use" for mild water retention -- not for hypertension. This represents a case where clinical trial data has outpaced regulatory recognition.

Oregano oil is a popular supplement marketed primarily for immune support and antimicrobial activity. The essential oil is rich in the phenolic monoterpenes carvacrol (typically 60-80%) and thymol (typically 1-5%), which demonstrate potent broad-spectrum antimicrobial activity in vitro against bacteria, fungi, and some parasites. However, the clinical trial evidence for oregano oil in humans is extremely limited and does not match its commercial popularity. One small open-label study (Chedid et al. 2014) included oregano as part of a multi-herb protocol for SIBO that showed equivalence to rifaximin, but oregano oil was not isolated as a single intervention. A Phase I trial of carvacrol confirmed safety in healthy subjects. No Commission E, ESCOP, or EMA monograph exists for oregano oil specifically. The herb is generally safe at recommended supplement doses, but essential oil ingestion carries inherent risks and should be distinguished from culinary use of dried oregano herb.

Panax ginseng (Korean ginseng) is one of the most extensively studied medicinal plants worldwide, with over 2,000 years of documented use in Traditional Chinese Medicine as the premier Qi tonic (Ren Shen). Its principal bioactive compounds, the ginsenosides (especially Rb1, Rg1, Rg3, Re, and Rd), act through multiple mechanisms including HPA axis modulation, nitric oxide synthesis, neuroprotection via BDNF/TrkB signaling, and immune cell activation. Clinical evidence from multiple RCTs and meta-analyses supports benefits for fatigue reduction, modest cognitive improvement (particularly memory), glycemic regulation in type 2 diabetes, and enhanced NK cell activity. The standardized extract G115 (4% ginsenosides) is the most extensively studied preparation. Panax ginseng holds Commission E and ESCOP approval as a tonic for fatigue and declining concentration, while the EMA/HMPC classifies it under traditional use for symptoms of asthenia. Despite broad evidence, the overall rating is B (Strong) rather than A because the evidence is fragmented across numerous indications without reaching definitive strength in any single condition, and many trials are of moderate quality with small sample sizes.

Passionflower is recognized by all major European monograph bodies (Commission E, ESCOP, WHO) for nervous restlessness and sleep disturbance, making it one of the most broadly endorsed herbs in this collection from a regulatory standpoint. However, the clinical trial evidence supporting these endorsements is limited in quantity and quality. The mechanism involves GABA modulation (both GABA-A and GABA-B receptors), with flavonoids (chrysin, apigenin, isovitexin) and direct GABA content as likely active constituents. One noteworthy trial found passionflower comparable to oxazepam for GAD. It has an excellent safety profile with virtually no reported adverse effects.

Pelargonium sidoides root extract EPs 7630 (Umckaloabo) is one of the best-evidenced herbal medicines in European phytotherapy, with 10+ RCTs involving over 2,000 patients demonstrating efficacy for acute bronchitis. It received full marketing authorization in Germany in 2005 -- not merely traditional use registration -- and has an EMA/HMPC monograph. The extract works through a unique triple mechanism: immunomodulation (cytokine and NK cell activation), antibacterial activity (anti-adhesion, not bactericidal), and cytoprotective/antiviral effects. It is one of the top-selling OTC medicines in German pharmacies. The evidence base is substantially stronger than for most herbal medicines, with robust meta-analyses showing reduced sick days and faster recovery from acute bronchitis.

See full monograph below.

Pycnogenol is a standardized extract of French maritime pine bark (Pinus pinaster) containing 65-75% procyanidins (oligomeric proanthocyanidins, OPCs). It is one of the most extensively studied botanical extracts, with over 100 clinical trials and 39+ RCTs across diverse indications. The strongest evidence supports its use in chronic venous insufficiency (CVI), where multiple RCTs have demonstrated significant reductions in leg edema, heaviness, and pain -- in one study, Pycnogenol alone was more effective than compression stockings. A 2025 meta-analysis of 27 RCTs confirmed significant blood pressure reductions (SBP -2.26 mmHg, DBP -2.62 mmHg). Additional evidence exists for blood glucose management, skin health, cognitive function, and joint health. Despite this extensive clinical portfolio, no European regulatory body (Commission E, ESCOP, EMA) has published a monograph for pine bark. This reflects the fact that Pycnogenol is a modern proprietary extract without the centuries of traditional European use that typically underpins regulatory monographs. The evidence base, while large, is concentrated among a small group of investigators with industry ties.

Ribwort plantain (Plantago lanceolata) is a traditionally important European respiratory herb approved by Commission E and ESCOP for catarrh of the airways and oral/throat mucosal inflammation. Its dual mechanism -- mucilage-based soothing of irritated membranes and iridoid glycoside-mediated anti-inflammatory action -- is well-supported by in vitro and preclinical evidence. However, robust clinical trial data is limited. It is primarily recommended for moderate chronic irritative cough, especially in children, where its excellent safety profile is advantageous. The EMA/HMPC classifies it under traditional use.

Pomegranate is a fruit with a long history in Ayurvedic and traditional medicine, now subject to considerable modern research interest for cardiovascular and prostate health. The fruit and its extracts are exceptionally rich in punicalagins, ellagitannins, and ellagic acid, which are potent antioxidants. Multiple meta-analyses of RCTs suggest a modest blood pressure-lowering effect, though individual trial results are inconsistent. Early research on PSA doubling time in prostate cancer patients generated significant excitement, but larger placebo-controlled trials failed to confirm the effect. No European regulatory body (Commission E, ESCOP, or EMA) has issued a monograph for pomegranate. It remains a food/dietary supplement with promising but unconfirmed therapeutic potential.

Primula veris (cowslip) is a key ingredient in two of Germany's most successful phytopharmaceuticals: Sinupret (for sinusitis) and Bronchipret (for bronchitis, in combination with thyme). As a single herb, it has Commission E and ESCOP approval for productive cough and bronchitis. The strongest clinical evidence is for the 5-herb combination Sinupret (BNO 1016), which has RCT evidence demonstrating efficacy in acute rhinosinusitis (healing rate 48.4% vs. 35.8% placebo). Sinupret is the only herbal product for rhinosinusitis with evidence from well-designed, adequately powered RCTs.

See full monograph below.

Pumpkin seed (Cucurbita pepo) is a well-tolerated European phytotherapeutic approved by Commission E for irritable bladder and BPH stages I-II. The landmark GRANU study (n=1,431) demonstrated clinically relevant IPSS reduction vs. placebo over 12 months. Its mechanism involves anti-androgenic, anti-inflammatory, and cholesterol metabolism effects. Exceptionally safe for long-term use, it occupies a unique niche as a mild, food-grade BPH treatment that patients can incorporate into their diet as whole seeds or take as standardized extracts.

Pygeum (Prunus africana) bark extract is a well-established European phytotherapeutic for BPH, with Cochrane review evidence from 18 RCTs (n=1,562) showing modest but significant symptom improvement. The standardized extract Tadenan has been a licensed medicine in France for decades. Mechanism involves anti-androgenic, anti-inflammatory (5-LOX inhibition), anti-proliferative, and bladder-protective effects. However, pygeum carries a unique ethical dimension: the tree is CITES Appendix II listed (since 1995) due to destructive bark harvesting in African montane forests, making sustainability a significant concern that distinguishes it from all other herbs in this collection.

Raspberry Leaf has been used by midwives and herbalists for centuries to prepare the uterus for labor and ease childbirth. However, this is one of the most significant disconnects between traditional practice and evidence in European phytotherapy. The EMA/HMPC has granted "traditional use" status -- but specifically for menstrual spasms, mouth/throat inflammation, and diarrhea, NOT for pregnancy or labor facilitation. The EMA explicitly does NOT recommend the traditional parturition use. Clinical evidence is sparse: only two small clinical studies and one recent observational study exist for pregnancy use, none of which provides definitive evidence of efficacy or safety. The active constituents (fragarine, tannins, flavonoids) are poorly characterized. A well-designed RCT is urgently needed.

Red Clover is a significant source of isoflavones (formononetin, biochanin A, genistein, daidzein) used primarily for menopausal hot flashes. Unlike soy isoflavones, Red Clover contains higher proportions of the methylated isoflavones formononetin and biochanin A. Meta-analyses show a statistically significant reduction in hot flash frequency (-1.73/day vs. placebo), with best results at doses of 80+ mg isoflavones/day for 12+ weeks. However, formal European regulatory recognition is limited -- there is no Commission E or ESCOP monograph specifically for menopausal use, and the EMA assessment is not as developed as for Black Cohosh or Vitex. Promensil is the most studied commercial product. Safety appears acceptable for up to 2 years, but uncertainty persists regarding use in hormone-sensitive cancers.

Red vine leaf extract (AS 195, marketed as Antistax) is a flavonoid-rich phytomedicine used for mild-to-moderate chronic venous insufficiency (CVI). Standardized to quercetin-3-O-beta-glucuronide, it has demonstrated significant edema reduction and symptom improvement in multiple RCTs at doses of 360-720 mg/day. The EMA/HMPC has granted traditional use status. It represents a well-tolerated option for early-stage CVI that has been marketed in France for over 70 years and is now available across multiple European countries.

Reishi (Ganoderma lucidum) is the "Mushroom of Immortality" in traditional Chinese medicine, with over 2,000 years of documented use for promoting longevity and vitality. Its primary bioactive constituents -- beta-glucan polysaccharides and ganoderic acid triterpenoids -- have demonstrated immune-modulating effects through activation of innate immune cells including macrophages, NK cells, and dendritic cells. Clinical studies, including a Cochrane review of five RCTs, support adjunctive use in cancer patients for immune function and quality of life improvements, though direct antitumor effects have not been demonstrated. Traditional indications for sleep, anxiety, and cardiovascular support are backed by preliminary mechanistic data but lack robust clinical trials. Reishi falls outside the European phytotherapy regulatory framework.

Restharrow root (Ononis spinosa) is a classic European irrigation therapy herb approved by the German Commission E and EMA/HMPC for flushing the urinary tract in inflammatory conditions and for prevention and treatment of kidney gravel. It has been a staple ingredient in German Blasen- und Nierentees (bladder and kidney teas) for centuries, often combined with birch leaf, goldenrod, and horsetail. Its key bioactive constituents include isoflavonoids (ononin, formononetin, sativanone, medicarpin), the seco-triterpenoid alpha-onocerin, and small amounts of essential oil. While preclinical research has identified plausible mechanisms -- including inhibition of renal hyaluronidase-1 by isoflavonoids and anti-adhesive activity against uropathogenic E. coli -- there are virtually no modern clinical trials in humans, making restharrow one of the most tradition-dependent herbs in the European pharmacopoeia.

Rhatany (Krameria lappacea, syn. K. triandra) is a South American shrub whose root has been used in European pharmacy since the 18th century primarily as an astringent for oral and pharyngeal inflammation. Commission E approved it for inflammation of the mouth and pharyngeal mucosa, and EMA grants traditional use status for minor inflammation of the oral mucosa and gums. The root is exceptionally rich in proanthocyanidin tannins (neolignans, including ratanhiaphenol) which exert astringent, anti-inflammatory, and antimicrobial effects by precipitating proteins on mucosal surfaces, forming a protective layer. Rhatany is commonly found in European herbal toothpastes and mouthwashes (notably Weleda Ratanhia products). Despite its long pharmaceutical history and continued presence in European pharmacies, no clinical trials have been conducted. ESCOP has not issued a monograph. The evidence base rests entirely on traditional use, pharmacological plausibility of tannin astringency, and regulatory approval.

Rhodiola rosea is the most formally recognized adaptogen in European phytotherapy, being the only herb with an EMA/HMPC monograph specifically for stress-related symptoms. The 2012 HMPC monograph approved it as a traditional herbal medicinal product for temporary relief of stress symptoms such as fatigue, exhaustion, and sensation of weakness. The SHR-5 standardized extract (3% rosavins, 1% salidroside) is the most clinically studied preparation, with RCTs demonstrating significant anti-fatigue effects, improved mental performance under stress, and potential antidepressant activity. The herb acts primarily through HPA axis modulation, monoamine neurotransmitter effects, and neuroprotective mechanisms. Safety is excellent with a very large therapeutic margin, but clinically relevant CYP3A4 and CYP2C9 inhibition warrants attention for drug interactions.

Rosehip (Rosa canina) powder has emerged as a promising nutraceutical for osteoarthritis, supported by a meta-analysis of three RCTs (Christensen et al. 2008) showing a small-to-moderate effect on pain (ES 0.37) and an NNT of 6. The proposed active constituent is a galactolipid called GOPO, which has demonstrated anti-inflammatory and antioxidant properties in vitro. ESCOP has published a monograph supporting use in osteoarthritis. The EMA/HMPC has a traditional use monograph (as a vitamin C source and for mild joint complaints). Commission E published a negative monograph for rosehip pseudo-fruit, citing insufficient evidence at the time. The clinical evidence is modest but consistent -- all three key trials (Warholm 2003, Rein 2004, Winther 2005) showed benefits over placebo. However, the evidence base is limited by small sample sizes, short durations, and sponsorship by a single manufacturer. Rosehip is distinct from other musculoskeletal herbs in that its mechanism appears to involve galactolipid-mediated inhibition of leukocyte chemotaxis rather than direct COX/LOX inhibition.

Rosemary is a traditional European medicinal herb approved by Commission E for dyspeptic complaints (internal use) and as supportive therapy for rheumatic diseases (external use). The EMA grants traditional use status for mild digestive disorders and mild muscle/joint pain. ESCOP has not published a monograph for rosemary. The leaf contains rosmarinic acid, carnosic acid, carnosol, and a complex essential oil rich in 1,8-cineole, camphor, and borneol. Clinical trial evidence is very limited -- the evidence base rests primarily on pharmacological plausibility, long traditional use, and the well-characterized antioxidant and spasmolytic properties of its constituents. Rosemary occupies a complementary role alongside peppermint and other carminatives in the European phytotherapy approach to functional dyspepsia.

Saffron (Crocus sativus) has emerged as one of the most promising herbal antidepressants, with multiple randomized controlled trials demonstrating that 30 mg/day of saffron extract is as effective as fluoxetine (20 mg/day) and imipramine (100 mg/day) for mild-to-moderate depression, while producing significantly fewer adverse effects. Its principal bioactive compounds -- crocin (a carotenoid glycoside) and safranal (a monoterpene aldehyde) -- exert antidepressant effects through serotonin reuptake inhibition, monoamine oxidase inhibition, NMDA receptor antagonism, and upregulation of BDNF. A 2024 meta-analysis of eight RCTs found no significant difference between saffron and SSRIs in reducing depressive symptoms (SMD = 0.10, 95% CI: -0.09 to 0.29), with saffron producing fewer adverse events. Despite this compelling clinical evidence, saffron lacks formal European monographs (Commission E, ESCOP, EMA/HMPC), largely because it originates from Persian and Ayurvedic rather than European herbal traditions.

Sage is a well-established European medicinal herb approved by Commission E, ESCOP, and EMA for excessive perspiration (especially menopausal hot flashes and night sweats), inflammation of the mouth and throat, and mild dyspeptic complaints. The leaf contains thujone-bearing essential oil alongside rosmarinic acid and other phenolic compounds. Clinical evidence for its anti-hydrotic (sweat-reducing) effect is moderate, supported by several open-label and a few controlled trials showing 50-64% reductions in hot flash intensity. Thujone content requires attention to dosage limits and duration; the EMA recommends limiting use of thujone-containing preparations to 2-4 weeks unless under medical supervision. Sage occupies a unique niche in phytotherapy as one of the few herbal medicines with a specific indication for hyperhidrosis.

Saw palmetto is the most extensively studied phytotherapeutic for BPH worldwide. The hexane extract (Permixon) has EMA "well-established use" status and has shown efficacy comparable to finasteride and tamsulosin in European trials. However, two major US trials (STEP, CAMUS) using ethanol/CO2 extracts found no benefit over placebo. This divergence -- driven by extract type, regulatory philosophy, and trial design -- represents the most significant EU-US split in phytotherapy evidence assessment.

Schisandra chinensis (Wu Wei Zi, "Five-Flavor Berry") is one of the few herbs that bridges both the traditional Chinese medicine and Russian/Scandinavian adaptogen research traditions. Its primary bioactive constituents are dibenzocyclooctadiene lignans (schisandrin, schisandrin B, gomisins), which demonstrate hepatoprotective effects through glutathione system enhancement and adaptogenic activity via cortisol modulation and HSP70 induction. Clinical evidence supports benefits for stress adaptation, hepatoprotection (liver enzyme normalization), and physical/mental performance under stress, though much of the research originates from Soviet-era studies and combination adaptogen formulas (ADAPT-232, Chisan) rather than standalone RCTs. The EMA/HMPC adopted a traditional use monograph (2017) for symptoms of mental and physical fatigue, though it lacks Commission E or ESCOP monographs.

Sea buckthorn is a thorny shrub native to Europe and Asia whose berries and seeds yield oils with a distinctive nutritional profile, notably rich in the rare omega-7 fatty acid (palmitoleic acid), along with vitamins C and E, carotenoids, flavonoids, and phytosterols. Used in both Traditional Chinese Medicine (Sha Ji) and European folk medicine, it has a long history for skin conditions, wound healing, and mucosal health. Clinical trials show benefits for skin hydration, elasticity, and epithelial integrity, with a notable RCT demonstrating improved vaginal epithelial integrity in postmenopausal women (though effects on vaginal dryness symptoms themselves were not significant). The oil contains over 190 bioactive compounds. No Commission E, ESCOP, or EMA monograph exists. Current evidence is preliminary but growing, with the unique omega-7 content and broad bioactive profile supporting continued investigation for dermatological and mucosal applications.

See full monograph below.

Shatavari (Asparagus racemosus) is considered the foremost women's health tonic in Ayurveda, where it is called the "Queen of Herbs" and used across all stages of female reproductive life -- from menstruation through menopause and lactation. The tuberous root contains steroidal saponins (shatavarins I-IV), isoflavones, racemosol, and mucilage with demonstrated estrogenic, galactagogue, antioxidant, and adaptogenic properties in preclinical studies. Limited clinical trials suggest modest benefits for lactation promotion (galactagogue effect) and menopausal symptoms. The name "Shatavari" translates to "she who possesses a hundred husbands," reflecting its traditional reputation as a female reproductive tonic and aphrodisiac. No European regulatory monographs exist, but shatavari is one of the most important herbs in the Ayurvedic Pharmacopoeia. Evidence is limited -- pharmacologically promising with deep traditional roots but insufficient clinical trial data by Western standards.

Slippery elm (Ulmus rubra) is a classic North American demulcent herb whose inner bark produces a thick mucilage when mixed with water. This mucilage forms a protective, soothing coating over irritated mucous membranes of the throat and gastrointestinal tract. It has deep roots in Native American traditional medicine and was adopted into the United States Pharmacopeia (USP) in the 19th century. The FDA classifies slippery elm bark as a safe and effective OTC oral demulcent, one of the few herbs with explicit FDA "safe and effective" recognition. Despite this regulatory recognition and centuries of traditional use, there are no published RCTs evaluating slippery elm as a monotherapy for any condition. The sole relevant clinical study used a multi-ingredient formula. The mucilage (approximately 7% of inner bark dry weight, composed of galactose, rhamnose, galacturonic acid, and 3-O-methylgalactose) provides the pharmacological rationale for the demulcent action. Slippery elm occupies a unique position: widely used, FDA-recognized, traditionally well-documented, but essentially unstudied in modern clinical trials. It has no European regulatory monographs (Commission E, ESCOP, EMA) as it is not part of the European phytotherapy tradition.

Soy Isoflavones are the most extensively studied phytoestrogens for menopausal symptoms, with dozens of RCTs and multiple meta-analyses. A 2025 meta-analysis (12 RCTs, n=533) confirms a statistically significant but modest effect on menopausal symptoms (Hedges' g = -0.25). However, a landmark 2024 meta-analysis demonstrated that soy isoflavones have NO effect on four key estrogenicity markers (endometrial thickness, vaginal maturation index, FSH, estradiol), fundamentally challenging the "phytoestrogen" classification. The breast cancer question has shifted from concern to cautious reassurance -- epidemiological data shows reduced risk with dietary soy intake, and post-diagnosis consumption is associated with 25% reduced recurrence. Thyroid effects are minimal (modest TSH elevation, no clinical significance in euthyroid individuals). The equol producer status (approximately 30% of Western populations) may be a key determinant of individual response.

Spearmint (Mentha spicata) tea has demonstrated significant anti-androgenic effects in women with PCOS and hirsutism across several randomized controlled trials, consistently reducing free testosterone levels while increasing LH, FSH, and estradiol. The key active compounds include rosmarinic acid (the dominant polyphenol, comprising up to 88% of total phenolics), the monoterpene carvone, and limonene. Spearmint is notable for being a widely available, food-grade herb with a favorable safety profile and genuine therapeutic potential -- a rarity in phytotherapy. Emerging evidence from double-blind RCTs also supports the use of high-polyphenol spearmint extract (900 mg/day) for cognitive enhancement, particularly working memory and attention in older adults and active populations.

St. John's Wort is the most thoroughly studied herbal antidepressant, with over 35 randomized controlled trials demonstrating efficacy equivalent to SSRIs for mild-to-moderate depression, with significantly fewer side effects. However, it has the most extensive and clinically dangerous drug interaction profile of any herbal medicine, primarily through potent induction of CYP3A4, CYP2C9, CYP1A2, and P-glycoprotein. These interactions are driven primarily by the constituent hyperforin. In Europe it is available as an approved medicine; in the US it is an unregulated dietary supplement.

St. John's Wort oil (Oleum Hyperici, "Red Oil") is a traditional European wound-healing preparation that is well-recognized in the German-speaking world but virtually unknown in Anglophone dermatology. The topical use is approved by Commission E and ESCOP for minor wounds, burns, and skin inflammation. Hyperforin is the primary wound-healing active compound, stimulating keratinocyte differentiation. Clinical evidence is limited but supportive, including a positive RCT for cesarean wound healing. Photosensitivity concerns, while valid for oral/systemic use, appear minimal for topical application at standard concentrations.

Stinging nettle leaf/herb is approved by Commission E and ESCOP for adjuvant treatment of rheumatic and arthritic conditions and as a diuretic for urinary tract inflammation. It acts through NF-kB inhibition, COX-1/2 inhibition, and H1-receptor antagonism. The Mittman (1990) study provided initial evidence for allergic rhinitis, and in vitro work shows multi-target anti-allergic mechanisms. The herb is distinct from nettle root (used for BPH) and should not be confused with it. Safety profile is excellent with minimal side effects.

Stinging nettle leaf has Commission E, ESCOP, and EMA recognition as an adjuvant in the treatment of arthritis and rheumatic conditions. Its anti-inflammatory mechanism centers on NF-kB pathway inhibition, TNF-alpha/IL-1beta suppression, and COX/LOX modulation via caffeic acid derivatives and flavonoids. Clinical evidence is more limited than for Devil's Claw or Willow Bark, consisting mainly of small trials and the distinctive practice of urtication (direct application of fresh nettle stings to painful joints). It serves best as an adjuvant therapy rather than a standalone treatment, and is notable for its excellent safety profile and nutritional density.

Tea tree oil is the best-studied topical antimicrobial essential oil, with strong evidence for acne (comparable to 5% benzoyl peroxide with fewer side effects) and broad-spectrum antifungal activity. It originates from the Australian Aboriginal tradition, not the European one, but has been assessed by the EMA/HMPC with a traditional use monograph. Commission E and ESCOP have not published dedicated monographs. The primary active compound, terpinen-4-ol, disrupts microbial cell membranes. A critical safety concern is oxidation -- fresh oil is a weak sensitizer, but oxidized oil has 3-fold increased allergenic potency. Contact allergy prevalence in patch-test populations ranges from 0.1% to 3.5%.

Thyme is one of the most widely approved and traditionally used respiratory herbs in European phytotherapy. It holds Commission E, ESCOP, and EMA/HMPC approvals for bronchitis and upper respiratory catarrh. Its best clinical evidence comes from combination products with primrose root (Bronchipret) rather than as monotherapy. A pivotal Phase IV trial (n=361) demonstrated that thyme-primrose combination reduced coughing fits 2 days faster than placebo. Thyme is considered very safe with essentially no reported adverse effects at therapeutic doses.

Tongkat Ali (Eurycoma longifolia) is a Southeast Asian medicinal plant with growing clinical evidence for testosterone support, stress hormone modulation, and ergogenic effects. Multiple RCTs have demonstrated modest improvements in testosterone levels, cortisol ratios, and subjective well-being in stressed and aging men, primarily using standardized water extracts (Physta/LJ100 at 200-400 mg/day). The active compounds include eurypeptides, quassinoids (eurycomanone), and glycosaponins, which appear to act through HPA axis modulation and sex hormone-binding globulin (SHBG) reduction rather than direct androgenic stimulation. No European regulatory monographs exist (Commission E, ESCOP, EMA), though the herb is approved in Malaysia as a traditional medicine. The evidence is moderate overall -- promising but limited by small trial sizes and the need for larger, independent confirmatory studies.

Tormentil (Potentilla erecta) rhizome is a highly astringent herb rich in tannins (15-22%, predominantly catechol-type including agrimoniin and pedunculagin) used traditionally in European phytotherapy for nonspecific acute diarrhea and inflammation of the oral and pharyngeal mucosa. It holds ESCOP and EMA/HMPC approval but lacks a Commission E monograph. Its primary mechanism is tannin-mediated astringency: tannins precipitate proteins on mucosal surfaces, forming a protective layer that reduces secretion, inflammation, and fluid loss. A small RCT in children with rotavirus diarrhea demonstrated reduced stool frequency and duration, but overall clinical evidence remains limited. Tormentil represents a classical European tannin drug (Gerbstoffdroge) with strong pharmacological plausibility but insufficient modern clinical trial data.

Tribulus terrestris is widely marketed as a testosterone booster and performance enhancer, but clinical evidence does not support testosterone-increasing effects. A 2025 systematic review of 10 studies found that 8 out of 10 studies showed no significant change in androgen levels. There is limited evidence (low quality) for modest improvement in sexual function and erectile dysfunction at doses of 400-750 mg/day, potentially through mechanisms unrelated to testosterone. The herb contains steroidal saponins, primarily protodioscin, whose concentration varies significantly by geographic origin (Bulgarian varieties have the highest content). In Ayurveda it is known as Gokshura and used as a urinary and reproductive tonic. No Commission E, ESCOP, or EMA monograph exists. The safety profile appears generally favorable at standard doses, though liver and kidney toxicity have been reported at high doses in case reports.

Triphala is the most widely used polyherbal formula in Ayurveda, consisting of equal parts dried fruits from three species: Amalaki (Emblica officinalis/Phyllanthus emblica), Haritaki (Terminalia chebula), and Bibhitaki (Terminalia bellirica). It functions as a gentle bowel regulator and antioxidant-rich GI tonic. Clinical trials demonstrate efficacy for chronic constipation (comparable to polyethylene glycol in one RCT), improvements in bowel habits, and benefits for dental/periodontal health. Key active compounds include gallic acid, ellagic acid, chebulinic acid, chebulagic acid, and high concentrations of vitamin C from Amalaki. Mechanisms include prokinetic effects, prebiotic activity supporting beneficial gut microbiota, antioxidant protection, and mild laxative action through anthraquinone content. No European regulatory monographs exist, but Triphala is one of the best-documented formulas in the Ayurvedic Pharmacopoeia of India.

Turkey Tail (Trametes versicolor) is one of the most extensively researched medicinal mushrooms, valued primarily for its immune-modulating polysaccharide complexes PSK (polysaccharide-K, marketed as Krestin) and PSP (polysaccharopeptide). PSK has been approved as an adjuvant cancer therapy in Japan since 1977 and has been studied in over 20 randomized controlled trials involving thousands of patients with colorectal, gastric, and lung cancers, with meta-analyses demonstrating statistically significant improvements in 5-year overall survival rates when combined with standard chemotherapy. PSP is approved as a Category II drug in China for similar indications. The primary mechanism involves beta-glucan-mediated stimulation of innate and adaptive immunity through TLR2 and Dectin-1 receptor activation, enhancing NK cell cytotoxicity, CD8+ T cell proliferation, and dendritic cell maturation. While the Japanese and Chinese clinical data are substantial, Western clinical research remains in early phases, and product standardization outside pharmaceutical-grade PSK/PSP remains a significant challenge.

Turmeric is approved in Europe as a traditional medicine for mild digestive complaints. Curcumin, its principal active compound, has potent anti-inflammatory and antioxidant activity in vitro but notoriously poor oral bioavailability. This has spawned a generation of enhanced formulations (Meriva, Longvida, Theracurmin) that dramatically improve absorption. Clinical evidence is most promising for osteoarthritis pain, with emerging data for IBD and metabolic syndrome. A rare but real hepatotoxicity signal has emerged, linked to the HLA-B*35:01 allele.

Valerian is the most traditional European sedative herb, with a documented history of use spanning over 2,000 years. The EMA/HMPC grants "well-established use" status to specific ethanol extracts for relief of mild nervous tension and sleep disorders. The key active constituent, valerenic acid, is a positive allosteric modulator of GABA-A receptors, with recently discovered activity at adenosine A1 receptors. Clinical evidence shows modest benefits for sleep quality and latency, but effects are not dramatic and may require 2-4 weeks of regular use. It is very safe, with an excellent tolerability profile even in elderly populations. Often combined with hops for sleep.

Vervain (Verbena officinalis) is a classic European folk medicine herb with a long history of use as a mild expectorant and anti-inflammatory. It holds EMA traditional use status for cough associated with colds and for mild menstrual pain, but lacks Commission E or ESCOP monographs. As monotherapy, there are no published RCTs. Its most significant modern clinical role is as a component of Sinupret (BNO 1016), the 5-herb combination product for acute rhinosinusitis, where it contributes anti-inflammatory and secretolytic properties alongside gentian root, elderflower, primrose, and sorrel. The iridoid glycosides verbenalin and hastatoside, along with the phenylethanoid verbascoside, are considered the primary active constituents. Evidence rating is minimal (E) for monotherapy.

Vitex agnus-castus is the premier European phytomedicine for premenstrual syndrome (PMS), cyclical mastalgia, and menstrual irregularities. It holds "well-established use" status from the EMA/HMPC and a positive Commission E monograph. Its mechanism is uniquely well-characterized among gynecological herbs: diterpenes (clerodadienols) act as dopamine D2 receptor agonists, reducing prolactin secretion from the anterior pituitary. This explains its efficacy in conditions linked to latent hyperprolactinemia. The Ze 440 extract (Zeller, 20 mg/day) and BNO 1095 extract (Bionorica) are the best-studied preparations. Meta-analyses of 13-14 controlled trials consistently show benefit for PMS symptom reduction.

White peony root (Bai Shao) is one of the most important gynecological herbs in Traditional Chinese Medicine, appearing in dozens of classical formulas for menstrual disorders, pain, and blood deficiency. Its principal active compound, paeoniflorin (a monoterpene glycoside comprising over 90% of Total Glucosides of Peony), has well-characterized anti-inflammatory, immunomodulatory, and antispasmodic properties. Clinical evidence comes primarily through classical combination formulas: Shakuyaku-kanzo-to (peony-licorice decoction) is used in Japan for acute muscle cramps, while Dang Gui Shao Yao San is studied for dysmenorrhea and gynecological complaints. Total Glucosides of Peony (TGP) is an approved drug in China since 1998 for rheumatoid arthritis adjunctive therapy, with meta-analyses supporting its efficacy combined with DMARDs and its hepatoprotective properties. Emerging preclinical and early clinical evidence suggests potential in PCOS via anti-androgenic mechanisms and in systemic lupus erythematosus.

Willow Bark holds EMA "well-established use" status for low back pain -- the highest evidence tier available for herbal medicines in Europe. At 240 mg salicin/day, it demonstrated non-inferiority to rofecoxib (Vioxx) 12.5 mg/day in a head-to-head RCT for low back pain, at roughly 40% lower cost. Critically, willow bark is NOT simply "natural aspirin": it does not acetylate COX enzymes, has a broader mechanism of action, and produces far less GI toxicity. Despite this evidence, it remains rarely used in US clinical practice.

Witch hazel is one of the most widely used astringent herbs in both European and North American traditions. It holds Commission E, ESCOP, and EMA approval for topical skin and hemorrhoid applications. Its tannin-rich bark and leaf extracts show genuine anti-inflammatory activity via NF-kB pathway inhibition, but clinical trial evidence for skin conditions (especially eczema) is limited and mixed. A key distinction exists between tannin-rich hydroalcoholic extracts (pharmacologically active) and commercially common steam-distilled witch hazel water (tannin-depleted, lower activity).

See full monograph below.

Yarrow (Achillea millefolium) is one of the oldest and most broadly used medicinal plants in European folk medicine, with Commission E approval for loss of appetite and dyspeptic complaints, and EMA traditional use registration for appetite loss, mild GI spasms, and minor wound treatment. Despite centuries of use and pharmacologically plausible mechanisms (bitter-tonic appetite stimulation, spasmolytic flavonoids, anti-inflammatory proazulenes), yarrow has virtually no modern clinical trial evidence. It exemplifies the gap between long-established traditional use and the absence of controlled human studies. ESCOP has not issued a monograph. The evidence rating is low, resting almost entirely on traditional use documentation, pharmacological plausibility, and expert consensus.